Imfinzi (durvalumab) is an intravenous immunotherapy used primarily for advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It is administered in cycles of 14 or 28 days, with each infusion lasting about one hour, and …
Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) characterized by slow growth and primarily affects B lymphocytes in the lymphatic system. It is the most prevalent form of low-grade lymphoma, often asymptomatic in early stages, and …
Dasatinib, known as Sprycel, is a powerful tyrosine kinase inhibitor used primarily to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It targets the BCR-ABL fusion protein, disrupting …
Firmagon, or degarelix, is a critical treatment for hormone-dependent prostate cancer, working as a gonadotrophin-releasing hormone antagonist to rapidly lower testosterone levels. This mechanism inhibits prostate cancer cell growth by blocking …
Zytiga, known generically as abiraterone, is a hormone therapy drug used to treat advanced prostate cancer, particularly in patients whose cancer has progressed despite previous treatments. It works by inhibiting testosterone production, crucial for …
Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma characterized by the uncontrolled growth of B lymphocytes in the mantle zone of lymph nodes. It often exhibits both indolent and aggressive traits, complicating diagnosis and …
Nerlynx (neratinib) is an oral tyrosine kinase inhibitor that targets the HER2 receptor, essential for treating HER2-positive breast cancer, especially in patients who have previously undergone trastuzumab therapy. By irreversibly inhibiting HER2 and …
Pazopanib, marketed as Votrient, is a targeted therapy used primarily for advanced kidney cancer, specifically renal cell carcinoma (RCC). It functions as a multi-kinase inhibitor, blocking tyrosine kinases that promote cancer cell growth and …
Chemotherapy is a fundamental treatment for Hodgkin’s lymphoma, utilizing powerful drugs to kill or slow cancer cell growth. Administered in cycles via IV, oral, or intramuscular methods, it aims to maximize remission and minimize recurrence …
Cyclosporine is a powerful immunosuppressant crucial for preventing organ rejection in transplants and managing autoimmune diseases like rheumatoid arthritis and psoriasis. Isolated from the fungus Tolypocladium inflatum in the 1970s, it selectively …
Tagrisso (osimertinib) is a targeted therapy for non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene. As a third-generation tyrosine kinase inhibitor (TKI), it effectively addresses the T790M …
Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, particularly those aged 65 and older, stemming from mutations in lymphocytes in the bone marrow. It can progress slowly or aggressively, with symptoms like fatigue and swollen lymph …
Chronic lymphocytic leukemia (CLL) is a prevalent blood cancer primarily affecting older adults, particularly those over 65. It arises from genetic mutations in B-cells or T-cells in the bone marrow, leading to excessive proliferation of …
Epkinly is an innovative oncology medication used to treat certain resistant cancers by inhibiting tumor growth and enhancing the immune response. It is particularly beneficial for patients with advanced cancer stages where traditional therapies are …
Neulasta is a pegylated granulocyte colony-stimulating factor (G-CSF) that helps increase white blood cell production, particularly neutrophils, to combat neutropenia caused by chemotherapy. Administered as a single subcutaneous injection of 6 mg, …
Atezolizumab, branded as Tecentriq, is an innovative immunotherapy drug primarily used to treat non-small cell lung cancer (NSCLC) and urothelial carcinoma. It functions by inhibiting the PD-L1 protein, which allows cancer cells to evade the immune …
Talvey (Talquetamab) is a novel treatment for relapsed or refractory multiple myeloma that works by binding to both GPRC5D on myeloma cells and CD3 on T-cells, enhancing the immune response. Clinical studies, including the LocoMMotion and MoMMent …
Nubeqa, or darolutamide, is a promising treatment for prostate cancer, particularly for nonmetastatic castration-resistant and hormone-sensitive metastatic forms. As an androgen receptor inhibitor, it blocks testosterone from fueling cancer cell …
Zejula (niraparib) is an oral PARP inhibitor used for treating recurrent ovarian cancer, particularly in patients previously treated with platinum-based chemotherapy. It is particularly effective for those with BRCA1 and BRCA2 mutations, as it …
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in the U.S., accounting for about one-third of cases, primarily affecting older adults, especially men in their mid-60s. It involves the rapid proliferation of …
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer affecting B-lymphocytes, accounting for about 25% of non-Hodgkin lymphoma cases in the U.S. Symptoms include swollen lymph nodes, fever, night sweats, and weight loss. Diagnosis …
Multiple myeloma is a rare blood cancer affecting plasma cells, crucial for antibody production. It occurs when these cells become malignant, leading to health issues like anemia and increased infection risk. The disease has different forms, …
Low dose chemotherapy (LDC), or metronomic chemotherapy, involves administering reduced dosages of chemotherapy agents continuously, unlike traditional high-dose regimens aimed at maximizing tumor cell death. This approach minimizes severe side …
Chronic lymphocytic leukemia (CLL) is a common cancer in adults, particularly those over 65, characterized by an accumulation of abnormal B lymphocytes in the blood and bone marrow. The disease can progress slowly, often requiring no immediate …
Idhifa (enasidenib) is a targeted therapy in tablet form, primarily prescribed at an initial dose of 100 mg once daily for adults with acute myeloid leukemia (AML) harboring IDH2 mutations. The maximum dose can be adjusted up to 200 mg based on …
Multiple myeloma, a type of bone marrow cancer, occurs when malignant plasma cells disrupt normal blood cell production, leading to complications such as anemia, bone pain, and increased infection risk. Symptoms include persistent bone pain, fatigue, …
Multiple myeloma is a rare blood cancer originating in the bone marrow, characterized by the proliferation of malignant plasma cells that disrupt normal blood cell production. Symptoms often go unnoticed in early stages but can include bone pain, …
Chronic lymphocytic leukemia (CLL) is a slow-progressing blood cancer characterized by the accumulation of abnormal lymphocytes in the blood and bone marrow. It predominantly affects older adults, with approximately 18,700 new cases expected in the …
Onureg, or azacitidine, is a crucial medication for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As a hypomethylating agent, it reactivates silenced genes linked to cancer progression, making it particularly beneficial …
The article discusses the significance of understanding biosimilars, particularly Amjevita, which is similar but not identical to its reference biologics due to variations in manufacturing processes. Amjevita is available in various forms and …
Bavencio is an FDA-approved monoclonal antibody that targets the PD-L1 protein, enhancing the immune response against tumors, particularly in Merkel cell carcinoma and urothelial carcinoma. It is administered via intravenous infusion, with an initial …
Chemotherapy is a vital treatment for cancer, especially for non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancer cases. It utilizes cytotoxic drugs to target and destroy rapidly dividing cancer cells by disrupting their …
Epkinly is a bispecific antibody targeting CD20 and CD3, representing a promising treatment for B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). It enhances the immune system’s ability to identify and eliminate malignant …
The article emphasizes the significance of being aware of the side effects associated with Loqtorzi, a medication for non-small cell lung cancer (NSCLC). Side effects can vary among patients and may include fatigue, nausea, liver function changes, …
The article discusses the diagnosis of Chronic Lymphocytic Leukemia (CLL), highlighting the combination of clinical evaluation and laboratory testing, often initiated by routine blood tests showing elevated lymphocyte counts. CLL is confirmed through …
Multiple myeloma, a challenging form of plasma cell cancer, primarily affects the bone marrow through the uncontrolled growth of plasma cells, leading to abnormal antibody production. This disease can manifest in various forms, ranging from …
Myelodysplastic syndromes (MDS) are hematological disorders characterized by ineffective blood cell production, primarily affecting older adults. Symptoms include fatigue, weakness, and increased infection risk, with fatigue being influenced by …
Trexall, known generically as methotrexate, is an effective medication for managing autoimmune diseases and certain cancers, classified as a disease-modifying anti-rheumatic drug (DMARD). It works by inhibiting folic acid metabolism, reducing …
Pemazyre (pemigatinib) is a targeted therapy for adults with unresectable locally advanced or metastatic cholangiocarcinoma that has FGFR2 alterations. It works by inhibiting the FGFR pathway, impacting tumor growth and cell survival. While it has …
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a condition marked by abnormal proteins produced by atypical plasma cells in the blood, commonly found in older adults and particularly prevalent among African Americans and men. Although …
Myelodysplastic syndromes (MDS) are a group of hematological disorders resulting in ineffective blood cell production and can lead to symptoms like anemia, fatigue, and an increased risk of infections. Most patients are elderly, often over 60, but …
Myelodysplastic syndromes (MDS) are a group of hematological diseases characterized by ineffective blood cell production and dysplastic changes in bone marrow, leading to low blood cell counts and a heightened risk of acute myeloid leukemia (AML). …
Ceritinib, known as Zykadia, is a targeted therapy for advanced non-small cell lung cancer (NSCLC) that is positive for the anaplastic lymphoma kinase (ALK) gene. As a tyrosine kinase inhibitor, it blocks the ALK enzyme, crucial for cancer cell …
Retevmo (selpercatinib) is a targeted therapy approved by the FDA for treating advanced non-small cell lung cancer (NSCLC) and medullary thyroid cancer with RET gene alterations. It works by inhibiting abnormal RET proteins that promote tumor growth, …
Yescarta (axicabtagene ciloleucel) is an innovative CAR T-cell therapy designed to treat specific blood cancers, notably diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma. This treatment involves collecting a …
The article discusses the recommended dosage and administration of Zydelig (idelalisib) for treating chronic lymphocytic leukemia (CLL). The standard dosage is 150 mg taken twice daily, with adjustments possible for side effects, particularly hepatic …
Epkinly (epcoritamab) is a groundbreaking treatment for diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, accounting for about 22% of new cases in the U.S. each year. This bispecific antibody targets CD3 on T …
Xtandi, or enzalutamide, is a revolutionary treatment for advanced prostate cancer, particularly effective in nonmetastatic castration-sensitive cases as per recent FDA approvals. By inhibiting the androgen receptor signaling pathway, Xtandi reduces …
Inlyta (axitinib) is a targeted therapy for advanced renal cell carcinoma (RCC), classified as a tyrosine kinase inhibitor (TKI) that blocks vascular endothelial growth factor receptors (VEGFRs) to inhibit tumor growth and angiogenesis. Approved by …
The article discusses various types of hormone therapy for prostate cancer, which aim to lower testosterone levels or block its effects on cancer cells. Key therapies include LHRH agonists (e.g., goserelin, leuprolide), anti-androgens (e.g., …
The article discusses the essential guidelines for using Rubraca, a medication for treating ovarian cancer, particularly in patients with BRCA1 or BRCA2 mutations. It highlights the need for regular monitoring through blood tests to detect potential …
Provenge, or sipuleucel-T, is the first FDA-approved therapeutic cancer vaccine for advanced prostate cancer, offering a novel approach to enhance the immune response in patients with this disease. Unlike preventive vaccines, Provenge is designed for …
Rydapt, or midostaurin, is an oral medication used to treat acute myeloid leukemia (AML) and systemic mastocytosis by inhibiting receptor tyrosine kinases, particularly FLT3, which is often mutated in AML. It enhances patient outcomes when combined …
Polivy (polatuzumab vedotin) is an innovative antibody-drug conjugate used in the treatment of diffuse large B-cell lymphoma (DLBCL), particularly for patients who have relapsed or are refractory to previous therapies. As the most common aggressive …
Myelodysplastic syndromes (MDS) are a group of blood disorders characterized by ineffective blood cell production, leading to conditions such as anemia, neutropenia, and thrombocytopenia. MDS primarily affects older adults, with a median diagnosis …
Chronic conditions, particularly refractory multiple myeloma, greatly affect individuals’ physical, emotional, and social well-being. Defined as long-lasting health issues, chronic diseases require ongoing management and often lead to …
Sunitinib, known by the brand name Sutent, is a targeted cancer therapy effective in treating advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) resistant to imatinib, and pancreatic neuroendocrine tumors (PNET). As a protein …
Capivasertib is an investigational drug targeting the PI3K/AKT/mTOR pathway, crucial for cell growth and often dysregulated in cancers like prostate cancer. By inhibiting AKT, Capivasertib aims to enhance existing treatments, particularly for …
Yescarta is a revolutionary CAR T-cell therapy approved for treating adult patients with relapsed or refractory large B-cell lymphoma, particularly non-Hodgkin’s lymphoma (NHL). It works by utilizing genetically modified T cells to target and …
Trelstar, a brand-name drug containing triptorelin, is a crucial hormone therapy for advanced prostate cancer, approved by the FDA for palliative treatment. As a gonadotropin-releasing hormone (GnRH) agonist, it suppresses testosterone production, …
Hodgkin Lymphoma (HL) is a cancer of the lymphatic system characterized by Reed-Sternberg cells and is one of the most treatable cancers, particularly when diagnosed early. It includes two main types: classical Hodgkin lymphoma, which comprises 95% …
The article discusses Nodular Sclerosis Hodgkin’s Lymphoma (NSHL), highlighting its unique characteristic of Reed-Sternberg cells, which arise from B-lymphocytes. NSHL spreads predictably, starting in one lymph node group, allowing for …
Nexavar, or sorafenib, is a targeted therapy primarily used for treating renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). As a multi-kinase inhibitor, it blocks receptor tyrosine kinases involved in tumor growth and angiogenesis, …
Myelodysplastic Syndromes (MDS) primarily affect older adults, particularly those aged 65 and above, but can also occur in younger individuals. MDS is characterized by abnormalities in hematopoietic stem cells in the bone marrow, leading to a …
The article discusses the mechanism of action and important considerations for the use of hydroxycarbamide (Hydrea) in cancer treatment. Hydroxycarbamide works by inhibiting ribonucleotide reductase, which is vital for DNA synthesis, leading to …
Bavencio (avelumab) is an immune checkpoint inhibitor used primarily for treating metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. It enhances the immune system’s ability to target cancer cells by …
Onivyde (irinotecan liposome injection) is a treatment primarily for metastatic pancreatic cancer in patients who have progressed after gemcitabine-based therapy. It functions as a topoisomerase inhibitor, disrupting DNA replication in cancer cells …
Vitrakvi (larotrectinib) is a tumor-agnostic targeted therapy approved by the FDA in 2018 for solid tumors with abnormal NTRK gene fusions. Its effectiveness is determined by specific genetic markers rather than tumor location. The recommended dosage …
Castleman disease is a rare immune dysregulation disorder characterized by abnormal lymphatic tissue overgrowth, leading to enlarged lymph nodes. It primarily manifests in two types: unicentric Castleman disease (UCD), involving a single lymph node …
Kymriah, the first FDA-approved CAR T-cell therapy, has significantly transformed cancer treatment, particularly for blood cancers like pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL). This innovative …
Immunophenotyping is a laboratory technique that utilizes antibodies to identify specific antigens on cell surfaces, primarily for diagnosing hematological cancers such as lymphomas and leukemias. The two main methods used are flow cytometry, which …
Ibrance (palbociclib) is an oral medication used to treat hormone receptor-positive, HER2-negative breast cancer by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), leading to cell cycle arrest and reduced cancer cell proliferation. Clinical …
Loqtorzi is an FDA-approved immune checkpoint inhibitor that targets the PD-1 receptor, enhancing immune response against cancers like metastatic melanoma and non-small cell lung cancer (NSCLC). Its benefits include improved survival rates, targeted …
The article emphasizes the importance of close monitoring for patients receiving Kymriah, particularly during the initial weeks post-infusion when side effects like Cytokine Release Syndrome (CRS) and neurological toxicities are most likely. Regular …
Immunotherapy is an innovative cancer treatment that utilizes the body’s immune system to identify and destroy cancer cells, contrasting traditional chemotherapy, which targets all rapidly dividing cells. Various immunotherapy types include …
Mektovi (binimetinib) is a targeted cancer therapy primarily used for melanoma patients, functioning as a MEK inhibitor to disrupt the MAPK signaling pathway, which is vital for cancer cell growth. It is often combined with Braftovi (encorafenib) to …
Eligard (leuprolide acetate) is an LHRH agonist that effectively suppresses testosterone production, primarily used for treating advanced and hormone-sensitive prostate cancer. Administered via subcutaneous injection, it works by inhibiting the …
Blincyto is a bispecific T-cell engager (BiTE) used to treat acute lymphoblastic leukemia (ALL) by targeting CD19 on B cells and CD3 on T cells, enhancing the immune system’s ability to eliminate cancer cells. The recommended dosage consists of …
Keytruda, a cancer immunotherapy, works by blocking the PD-1 receptor, enhancing T cell activation and promoting anti-tumor immunity. This mechanism allows T cells to recognize and attack cancer cells more effectively. The effectiveness of Keytruda …
Casodex is a prescription medication used to treat stage D2 metastatic prostate cancer by acting as an androgen receptor inhibitor, blocking testosterone’s effects on cancer cells. It is commonly administered with a luteinizing …
Midostaurin, marketed as Rydapt, is a kinase inhibitor targeting the FLT3 mutation, crucial for treating acute myeloid leukemia (AML) and systemic mastocytosis. In AML, Rydapt is typically prescribed at a dosage of 50 mg twice daily, starting on day …
Multiple myeloma, also known as Kahler’s disease, is a rare blood cancer affecting plasma cells, which are vital for immune function. Malignant plasma cells produce abnormal proteins, leading to health issues like anemia, bone pain, and kidney …
Onivyde (liposomal irinotecan) is an FDA-approved chemotherapy drug effective for treating metastatic pancreatic adenocarcinoma, especially in patients who have previously received gemcitabine-based therapy. Its unique liposomal formulation enhances …
Gleevec, a tyrosine kinase inhibitor approved by the FDA, plays a crucial role in treating various cancers, including Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Clinical studies show …
Chronic Myeloid Leukemia (CML) is a hematologic malignancy caused by genetic mutations in bone marrow stem cells, leading to an excess of mature white blood cells. It is often asymptomatic in early stages and detected through routine blood tests. CML …
Augtyro, or repotrectinib, is a novel medication designed for treating non-small cell lung cancer (NSCLC) with ROS1 gene fusions, particularly beneficial for patients whose cancer has progressed after previous therapies. It works by inhibiting …
Treanda, or bendamustine, is a chemotherapy agent approved by the FDA in 2008, used primarily for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). It functions as an alkylating agent, disrupting DNA synthesis and inducing …
Truxima (rituximab-abbs) is a monoclonal antibody that targets CD20 on B-cells, effectively reducing inflammation and symptoms of autoimmune diseases like rheumatoid arthritis, lupus, and certain cancers, including non-Hodgkin lymphoma and chronic …
Onivyde (irinotecan liposome injection) plays a vital role in treating pancreatic cancer, especially for patients with metastatic disease after gemcitabine-based therapy. This drug enhances the delivery of irinotecan to cancerous tissues while …
The article discusses Chronic Lymphocytic Leukemia (CLL), a common blood cancer affecting B cells, and its potential hereditary nature. Research shows that about 5%–10% of cancers may be linked to inherited genetic changes, emphasizing the importance …
Poteligeo (mogamulizumab) is a monoclonal antibody targeting CCR4, primarily used for treating relapsed or refractory mycosis fungoides (MF) and Sézary syndrome, types of cutaneous T-cell lymphoma (CTCL). It recruits immune effector cells to …
Cabozantinib, marketed as Cabometyx, is a targeted therapy that inhibits key receptor tyrosine kinases (RTKs) like VEGFR, MET, and AXL, which are crucial for tumor growth and metastasis. It is indicated for advanced renal cell carcinoma (RCC) after …
Preventive chemotherapy, also known as adjuvant chemotherapy, is a treatment administered after primary cancer treatments like surgery to eliminate any remaining cancer cells and reduce the risk of recurrence. It involves the use of cytotoxic drugs …
The article discusses the importance of lymphocyte levels in diagnosing and managing lymphoma. Normal lymphocyte counts range from 1,000 to 4,800 cells per microliter in adults, with deviations indicating potential health issues. Elevated lymphocyte …
Neulasta, or pegfilgrastim, is a biologic medication designed to prevent neutropenia, a common side effect of chemotherapy characterized by low neutrophil counts. By stimulating bone marrow, Neulasta enhances white blood cell production, thus …
The article discusses Truxima, the first biosimilar of the biologic rituximab, highlighting its role in making healthcare treatments more affordable. Truxima, a monoclonal antibody targeting CD20 on B-cells, is effective for conditions like …
Tezspire (tezepelumab-ekko) is a groundbreaking monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a cytokine that plays a crucial role in asthma and chronic allergic conditions. Unlike traditional biologics, Tezspire …
Thrombocytopenia is a condition characterized by a low platelet count in the blood, which can lead to excessive bleeding and bruising. Normal platelet levels range from 150,000 to 450,000 platelets per microliter, with thrombocytopenia diagnosed at …
R-ICE (Rituximab, Ifosfamide, Carboplatin, and Etoposide) is a chemotherapy regimen primarily used for treating relapsed or refractory non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. It combines an immunotherapy component (Rituximab) with …
Gilotrif, or afatinib, is a targeted therapy for non-small cell lung cancer (NSCLC) that specifically inhibits the epidermal growth factor receptor (EGFR), making it effective for patients with certain genetic mutations. Classified as a tyrosine …
The article discusses multiple myeloma, a hematological malignancy originating from plasma cells in the bone marrow. It highlights risk factors such as advanced age, racial background, and family history. Common symptoms include bone pain, fatigue, …
Summary: Sprycel (dasatinib) is an ABL1 tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), significantly improving survival outcomes and enabling some patients to achieve treatment-free …
Acute Myeloid Leukemia (AML) is a blood cancer primarily affecting myeloid cells in the bone marrow and is most common in adults, with an average diagnosis age of 68. Symptoms develop rapidly and can include fatigue, frequent infections, easy …
Blood tests are critical for diagnosing multiple myeloma, often identifying the disease before symptoms appear. Routine blood tests can reveal abnormalities such as monoclonal proteins (M proteins) produced by malignant plasma cells, helping to …
Mekinist, or trametinib, is a MEK inhibitor used primarily to treat advanced melanoma, especially in patients with specific BRAF mutations (V600E or V600K). Approved by the FDA in 2013, it serves as a systemic oral therapy for patients with …
The article discusses various treatment options for multiple myeloma, a type of blood cancer affecting plasma cells. It outlines five main categories of therapies: 1. Chemotherapy Agents: Common agents like Melphalan and Cyclophosphamide target …
The article discusses the role of myeloblasts in hematopoiesis, highlighting their origin from myeloid progenitor cells and their significance in the formation of granulocytes, which are crucial for the immune response and inflammation regulation. …
The article discusses the side effects, dosage guidelines, financial considerations, and patient experiences related to Carvykti, a CAR-T cell therapy for relapsed or refractory multiple myeloma. Common side effects include cytokine release syndrome …
Zytiga, or abiraterone acetate, is an oral medication used primarily for metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting the CYP17 enzyme, reducing androgen production and thus lowering testosterone levels, which can …
The article discusses the distinctions between relapsed and refractory acute myeloid leukemia (AML), emphasizing their different clinical implications. Refractory AML occurs when patients do not achieve remission after two cycles of chemotherapy, …
The article emphasizes the importance of awareness regarding drug interactions while using Sprycel (dasatinib), a medication for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Understanding these interactions is essential for …
Imbruvica (ibrutinib) is a targeted cancer therapy that acts as a Bruton’s tyrosine kinase (BTK) inhibitor, primarily used to treat blood cancers like mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstrom’s …
The article “The Hidden Dangers of Chemotherapy: Unraveling Cardiotoxicity” explores the cardiotoxic effects of chemotherapy, particularly from drugs like anthracyclines (e.g., doxorubicin). It identifies various forms of cardiotoxicity, …
Pemgarda is a monoclonal antibody medication used to manage inflammatory conditions, particularly systemic juvenile idiopathic arthritis (sJIA) and macrophage activation syndrome (MAS). It works by inhibiting the interleukin-1 (IL-1) signaling …
